Monsanto (MON) stock continues to deliver a favorable performance among other agribusiness stocks (XLB) so far this year. It has risen 11.0% YTD (year-to-date), outperforming the S&P 500, which has risen 8.0%. As the company waits to be merged with Bayer, its stock price is gradually climbing to $128, which is the deal price.
As of August 18, 2017, the mean consensus analyst rating for Monsanto (MON) stock was 2.5 with a “buy” recommendation for the next 12-month period. Of the 18 analysts surveyed by Reuters, two have a “strong buy” recommendation on the stock for the next 12 months.
We can see in the above graph that the most recent analyst recommendations show one more analyst with a “buy” recommendation, taking the total to six “buy” recommendations. Thus the number of analysts recommending a “hold” is one less, or ten analysts.
The consensus mean price target for Monsanto (MON) is $124 as of August 18, 2017. However, the median price target is $128, which is Monsanto’s acquisition price. That’s almost 7.0% higher than the closing price of $116.80 on August 18. However, when compared with the median price target, there’s an upside of almost 9.5%.
Next, let’s look at FMC (FMC).